⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

IQVIA removed two pandemic-related and technology obsolescence risks while adding an environmental sustainability risk, reflecting a shift away from COVID-19 concerns toward ESG compliance challenges. Seven risks underwent substantive modifications, including those addressing R&D Solutions liability, IT systems vulnerabilities, and industry dynamics, suggesting IQVIA refined its disclosure of existing operational and competitive pressures. The net addition of only one new risk against 54 unchanged risks indicates relatively stable risk positioning, with the company maintaining focus on long-standing challenges in biopharmaceutical outsourcing trends, competition, and operational execution.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟢 New in Current Filing Increasing focus on environmental sustainability and social initiatives could increase our costs, and inaction could harm our reputation and adversely impact our financial results. 🔒

🔴 No Match in Current Filing Our business and operations have been and may in the future be adversely affected by the novel coronavirus (COVID-19) pandemic. 🔒

🔴 No Match in Current Filing If we do not keep pace with rapid technological changes, our services may become less competitive or obsolete. 🔒

🟡 Modified Our Research & Development Solutions business could subject us to potential liability that may adversely affect our results of operations and financial condition. 🔒

🟡 Modified IT systems and Information 🔒

🟡 Modified Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate. 🔒

🟡 Modified Risks Relating to Our Industry 🔒

🟡 Modified Market Forces 🔒

🟡 Modified The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change. 🔒

🟡 Modified We may be affected by healthcare reform and potential additional reforms, which may adversely impact the biopharmaceutical industry and reduce demand for our services or negatively impact our profitability. 🔒

10 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →